Pfizer prepares to request authorization for its vaccine in the US

Nicolás Maduro says that if the opposition wins the legislative elections, he’ll go away the Presidency

The president of Venezuela assured this throughout a marketing campaign occasion for the elections this Sunday. The opposition led by Juan Guaidó doesn't...

5 killed by man intentionally operating into pedestrians in German Trier

In keeping with the police, the 51-year-old man who killed no less than 5 individuals, together with a child, and injured a number of...

Europe met its first local weather objective: in 30 years it decreased polluting emissions by 24%

European governments ought to approve on the summit on December 10 the discount of emissions as much as 55% for the following 10 years.Europe...

Germany outlaws the neo-Nazi group Sturmbrigade 44, an armed gang with a presence in 4 federal states

The German Ministry of the Inside has decreed the outlawing of the neo-Nazi group Wolfbrigade 44, often known as Sturmbrigade 44 (Wolf Brigade 44...

The unimaginable story of Imaad Zuberi, the ‘mercenary’ donor

Seen as "the individual with one of the best connections," Zuberi "bought" entry to highly effective individuals in change for hundreds of thousands. ...

The American Pharmacist Pfizer It is preparing to immediately request the emergency approval of its vaccine against covid-19, which has already exceeded the safety requirements set for its phase 3 trials, according to the company’s CEO, Albert Bourla, on Tuesday.

Bourla spoke this way in a forum organized by The New York Times and in another of the specialized health medium STAT News, after his company and its partner BioNTech announced on November 9 that the vaccine it is more than 90% effective.

Meet the requirements

“We are very close to requesting the emergency clearance& rdquor ;, said the main person in charge of the pharmaceutical company, who did not want to give a precise date for this expected step.

According to Bourla, Pfizer has already collected the safety data required by the health authorities, which require manufacturers to follow up for two months of at least half of the people who received the vaccine during phase 3 trials.

In the tests, which began last July, about 44,000 people have participated and, according to the companies, the vaccine has shown a effectiveness greater than 90% in participants with no previous evidence of infection.

Successful vaccines

Following the announcement by Pfizer and BioNTech, this Monday the biotech Modern released test results of its vaccine project, which point to an effectiveness of around 94%.

Bourla, on the STAT News forum, said he was relieved to learn that there is another successful vaccine and was confident that there is still more, since global demand It will exceed the capacity of any company.



Related Articles